Psychedelic Policy Briefing 8.14.26
In this week’s Psychedelic Policy Briefing, investigative journalist Jack Gorsline digs into the details of developments that could impact research into psychedelic-assisted therapies including multi-site VA clinical trials. In Washington D.C., the FDA has finalized its guidance on clinical investigations into psychedelic-assisted therapies. The agency set a September hearing, with two deadlines for comments coming in the next two weeks. Across the country in Silicon Valley, contract research organization ICON officially inked a deal to bring Anthropic’s Claude AI tool into clinical trials that move psychedelic-assisted therapies forward.
VA Launches Multi-Site Psilocybin Clinical Trial
On August 5, the U.S. Department of Veterans Affairs (VA) launched PIVOT, a five-site clinical trial evaluating the therapeutic use of psilocybin for veterans with treatment-resistant depression. The trial is investigating COMP360, a patented synthetic crystallin form of psilocybin developed by Compass Pathways. Patent approval for COMP360 was controversial and Compass is currently targeting a Q4 2026 New Drug Application (NDA) for the compound which is the center of its proposed “psychological support” model for treatment-resistant depression.
The two-dose comparison study will take place at VA facilities in Birmingham, Tuscaloosa, Portland, Philadelphia, and Puget Sound. According to the VA, the COMP360 investigation is one of 20 active clinical trials involving psychedelic compounds taking place across its healthcare network.
The trial establishes safety parameters and dosing protocols for veterans in the study which moves Compass forward as a frontrunner in the psychedelic-assisted therapy market. The outcome of the trial may determine if COMP360 takes the lead for a psilocybin therapy reimbursed by insurance.
FDA Finalizes Clinical Guidance Psychedelic Drugs and Schedules September Public Hearing
The FDA Center for Drug Evaluation and Research (CDER) finalized on July 14 its formal guidance document, Psychedelic Drugs: Considerations for Clinical Investigations. The document sets evidentiary standards for new drug applications establishing explicit expectations for functional unblinding mitigations, abuse-potential risk evaluations, and post-marketing risk evaluation and mitigation strategies (REMS).
To gather public comment, the FDA has scheduled a public hearing for September 14, 2026, titled “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs” (Docket FDA-2026-N-7542). The hearing seeks input on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings. Requests to present are due August 21, and written comments close October 5.
The FDA explicitly excludes comments on legalization, decriminalization, state and local program merits, scheduling, and religious or ceremonial use, while welcoming data from state programs. Requests for information by the federal Health Resources and Services Administration closed this week on August 13.
ICON Inks Deal with Anthropic to Incorporate AI into Future Clinical Trials
As first reported by Fierce Biotech, prominent contract research organization ICON has established a multi-year collaboration with artificial intelligence firm Anthropic to integrate it Claude AI tool into clinical trial operations, a move that could reshape how drug companies design and execute development programs. The partnership will utilize Anthropic’s life sciences team to bolster ICON’s agentic AI platform, Orbis, aiming to improve on-site artificial intelligence capabilities, study feasibility and trial protocol designs.
According to Anthropic’s Pip White, operational challenges such as study enrollment cause delays in up to 80% of trials. By deploying Claude to detect real-time enrollment risks and automate repetitive tasks, the companies hope to clear traditional bottlenecks and accelerate the overall clinical development process.
The collaboration comes as Anthropic deepens its ties to the pharma industry, despite recent regulatory friction at the federal level. Earlier this year, the Department of Health and Human Services restricted employee use of Claude, and U.S. President Donald Trump sought to block the company from federal contracts following disputes with the Department of Defense. Anthropic had sought assurances from the Pentagon that Claude would not be used for fully autonomous weapons or mass surveillance of Americans. The Pentagon said it would follow existing laws on AI and insisted on access without any limitations.
Undeterred, Anthropic recently acquired AI startup Coefficient Bio in a $400 million deal, secured an enterprise partnership with Bristol Myers Squibb and added Novartis CEO Vas Narasimhan to its board of directors. For the psychedelic medicine sector, ICON’s adoption of frontier AI signals an ongoing shift toward expanded use of artificial intelligence in drug development. If successful, these tools will shape how psychedelic drug developers navigate regulatory protocols and manage patient enrollment.
Note: This article was originally published by Psychedelics Today, and was produced in partnership with Psychedelic State(s) of America, a nonprofit-sponsored news organization dedicated to rigorous independent psychedelic journalism. Learn more about PSA’s Media Partnerships Program and donate to The PSA Media Fund.